Latest Breaking News On - Comprehensive treatment - Page 1 : comparemela.com

1. Progression-free survival in NSCLC was found to be significant with HR 0.41 compared to breast cancer which was non-significant with HR 0.78. 2. Grade 2 or worse adverse events occurred 41% in the standard-of-care group vs 62% in the SBRT group. Evidence Rating Level: 1 (Excellent) Study Rundown: The treatment paradigm for metastatic cancer

Rating levelComprehensive treatmentOligometastatic cancersLong term resultsOligometastatic cancerRadiation therapyStereotactic body radiotherapyChronic disease